Format

Send to

Choose Destination
Skin Therapy Lett. 2001 Dec;6(13):1-2.

Update on the botulinum neurotoxins.

Author information

1
Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Abstract

The botulinum neurotoxins (BTX) are an exciting group of therapeutic agents with dramatically expanding clinical indications. The US FDA has approved BOTOX (BTX-A, Allergan) and Myobloc (BTX-B, Elan Pharmaceuticals) for the treatment of cervical dystonia. TPP Canada has also approved BOTOX for the treatment of glabellar frown lines. The US FDA is expected to approve this new indication before the end of 2002. These changes will dramatically expand the marketing of BTXs. Concerns about risks and side-effects diminish as clinical experience increases with this "most poisonous of poisons". In particular, the incidence of secondary resistance to the toxin's effect has been dramatically diminished with the reduction of the non-toxic protein in current batches of BOTOX.

PMID:
11813096
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center